News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

The Painful Problem of Biosimilars in the Clinic

May 11, 2023
Howard S. Hochster, MD
OncologyONCOLOGY Vol 37, Issue 5
Volume 37
Issue 5
Pages: 200-201

Co-editor-in-Chief Howard S. Hochster, MD, discusses persistent obstacles to the effective use of biosimilars in clinical practice.

TABLE. FDA-Approved Oncology Drug Biosimilars as of April 2023

TABLE. FDA-Approved Oncology Drug Biosimilars as of April 2023

Just this week I ordered erythropoietin for a patient with chemotherapy-induced anemia. It was obvious, and the treatment was completely indicated. However, my electronic medical records order set had it listed as epoetin alfa (Procrit), so it took many hours and emails to eventually get epoetin alfa-epbx (Retacrit) approved by his insurance.

Why the major hassle for the use of biosimilar drugs (Table)? Why can’t we just order erythropoietin, filgrastim (Neupogen), bevacizumab (Avastin), or trastuzumab (Herceptin) and receive approval for any of the biosimilars?

The approval process for biosimilars is a result of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), a part of Obamacare. This congressional act was meant to parallel the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, for generic drugs, but sadly, the FDA has inadvertently undermined this process and created a lot of pain in the clinic.

The Hatch-Waxman Amendments created an important pathway for generic drugs, which allowed compounds of an identical chemical structure and bioequivalence to be approved without clinical trials. However, with the advent of “biologic” compounds that are not synthesized, but rather harvested from cell cultures, the drugs would never be chemically identical. Note: Even original brand compounds are not identical to themselves after a few years due to biological “drift”!

Therefore, the BPCI Act created an alternative pathway for biologically manufactured macromolecules to be considered “biosimilar.” If the drug acts on the same target and is considered “highly similar with no meaningful clinical differences,” it can be approved as a biosimilar. The preponderance of data required is preclinical, with laboratory analyses and binding assays, for example. In addition, one clinical trial is required to demonstrate the equivalent clinical activity to the originator molecule. If the agent is approved based on 1 trial, the biosimilar receives all the FDA-approved use indications that apply to the originator.

Then there is the problem of further FDA regulation. The FDA has legitimate concerns about monitoring the clinical activity and toxicity of these biosimilars through the “pharmacovigilance” program. To better track these varied biosimilars, the FDA issued a guidance in 2017 requiring all biologics to append the generic name with a 4-letter suffix, which should be random and of no meaning. This would allow better tracking of any problems with a particular biosimilar from a certain manufacturer.

However, by requiring the suffix, the FDA created a usage nightmare. Each biosimilar has its own identity today as a “branded biosimilar” (eg, for bevacizumab, Avastin is the originator and bevacizumab-awwb [Mvasi], bevacizumab-bvzr [Zirabev], and bevacizumab-maly [Alymsys] are all biosimilars). In addition, each of these drugs has its own J-code for billing. As a result, it becomes a game of ordering a biosimilar, insurance denying, and then trying to guess which one they will cover for payment. We have to reorder the drug with the correct biosimilar for which the insurer will pay. This is undesirable in a number of ways: (1) causes confusion in ordering the proper biosimilar, (2) is a waste of time for approvals and correction of orders, (3) requires additional pharmacy space and effort to stock multiple biosimilars because we cannot predict which one will be reimbursed, and (4) results in a lack of real competition between biosimilars, resulting in less competition and price reduction.

The need for pharmacovigilance should be balanced against the downstream pain experienced every day in the clinic. The drugs can be traced by manufacturer and lot number without suffixes and branded biosimilars (as with generic drugs). This is a case of “belt and suspenders,” and the belt is way too tight!

We should also note that clinicians have no scientific basis for preferring 1 approved biosimilar over another. We do not see the data on approvals and have to look hard to even find the manufacturer. To date, no biosimilar product has failed to live up to expectations as a drug compared with the originator drug, yet we experience the pain of prescribing biosimilars daily in the clinic.

Download Issue PDFDownload PDF
Articles in this issue

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
The Painful Problem of Biosimilars in the Clinic
The Painful Problem of Biosimilars in the Clinic
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Related Videos
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.
After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.
An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.
An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.
An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.
Expert in oncology
Expert in oncology
Related Content

T-DXd Produces Durable Responses in HER2-Positive Solid Tumors

June 5th 2023

Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

April 17th 2023

CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors

June 3rd 2023

Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology

June 28th 2022

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20th 2023

ICIs May be a Safe Option in Cancer Regardless of HIV Diagnosis

May 19th 2023

T-DXd Produces Durable Responses in HER2-Positive Solid Tumors

June 5th 2023

Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

April 17th 2023

CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors

June 3rd 2023

Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology

June 28th 2022

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20th 2023

ICIs May be a Safe Option in Cancer Regardless of HIV Diagnosis

May 19th 2023

T-DXd Produces Durable Responses in HER2-Positive Solid Tumors

June 5th 2023

Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

April 17th 2023

CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors

June 3rd 2023

Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology

June 28th 2022

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20th 2023

ICIs May be a Safe Option in Cancer Regardless of HIV Diagnosis

May 19th 2023
Related Content

Trastuzumab deruxtecan may become a new therapy option for patients with HER2-positive tumors, according to an expert from The University of Texas MD Anderson Cancer Center.

T-DXd Produces Durable Responses in HER2-Positive Solid Tumors

June 5th 2023
Article

Trastuzumab deruxtecan may become a new therapy option for patients with HER2-positive tumors, according to an expert from The University of Texas MD Anderson Cancer Center.


Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

April 17th 2023
Podcast

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.


CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors

CLDN6 CAR T-cell Therapy Yields Positive Response in Advanced Solid Tumors

June 3rd 2023
Article

Results from a phase 1/2a trial show that efficacy was maintained when BNT211 was used with or without a CLDN6-encoding mRNA vaccine for patients with relapsed/refractory advanced solid tumors.


Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology

Oncology Peer Review On-The-Go: Financial Conflicts of Interest Among Junior Faculty in Hematology and Oncology

June 28th 2022
Podcast

Suneel D. Kamath, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on how financial conflicts of interest correlate with success of early-career academic oncologist.


The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20th 2023
Article

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.


Patients with human immunodeficiency virus and cancer may derive clinical benefit from immune checkpoint inhibition with no excess toxicity in non–small cell lung cancer and other cancers.

ICIs May be a Safe Option in Cancer Regardless of HIV Diagnosis

May 19th 2023
Article

Patients with human immunodeficiency virus and cancer may derive clinical benefit from immune checkpoint inhibition with no excess toxicity in non–small cell lung cancer and other cancers.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.